# Hyaluronic Acid for Hypofractionated Prostate Radiotherapy

> **NCT02165020** · PHASE2 · UNKNOWN · sponsor: **Hospices Civils de Lyon** · enrollment: 36 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DEVICE:** Hyaluronic acid (Macrolane VRF 30®, Q-MED)

## Key facts

- **NCT ID:** NCT02165020
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-11
- **Primary completion:** 2017-05
- **Final completion:** 2017-05
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2016-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02165020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02165020, "Hyaluronic Acid for Hypofractionated Prostate Radiotherapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02165020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*